Khavinson short peptide bioregulator (cartilage-targeted)
A very short synthetic peptide (Ala-Glu-Asp-Lys) from the Russian Khavinson bioregulator family, researched for cartilage and joint health.
| Class / type | Khavinson short peptide bioregulator (cartilage-targeted) |
|---|---|
| Category | Longevity & Cellular |
| Status (Jul 2026) | Research use only |
The proposed mechanism is epigenetic: the peptide is thought to enter cells and bind DNA in chondrocytes, modulating expression of genes involved in collagen II synthesis and matrix regulation.
Researched and marketed abroad for joint and cartilage support, musculoskeletal aging, and connective tissue repair.
Reported in Russian studies to support cartilage regeneration and reduce age-related joint decline; peptide is small and reported to be well tolerated.
Evidence is almost entirely Russian observational and animal data with essentially no independent Western clinical trials; efficacy in humans is unproven; purity and sourcing are unregulated.
Bioregulator enthusiasts report subjective joint comfort, though sentiment rests on anecdote rather than controlled data.
NOT FDA-approved and not recognized as a drug in the United States; sold only as a research or supplement-grade compound not authorized for human treatment.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.